Obstruction clinical presentations

Clinical Presentation of Chronic Obstructive Pulmonary Disease... 

Botulism. Clinical features include symmetric cranial neuropathies (i.e., drooping eyelids, weakened jaw clench, and difficulty swallowing or speaking), blurred vision or diplopia, symmetric descending weakness in a proximal to distal pattern, and respiratory dysfunction from respiratory muscle paralysis or upper airway obstruction without sensory deficits. Inhalational botulism would have a similar clinical presentation as food-borne botulism however, the gastrointestinal symptoms that accompany foodborne botulism may be absent. 

The fatty streak, which is found at a young age ubiquitously among the world s population, consists of smooth muscle cell aggregates surrounded by cholesteryl ester deposits it is a sessile lesion that does not obstruct and presents no clinical symptoms. 

Patients with lung cancer frequently have numerous concurrent medical problems. Such problems may be related to invasion of the primary tumor and its metastases, paraneoplastic syndromes (see clinical presentation, above), chemotherapy and radiotherapy toxicity, or concomitant disease states (e.g., cardiac disease, renal dysfunction, chronic obstructive pulmonary disease, asthma, or diabetes). Depression is also common and sometimes persistent in patients with SCLC and NSCLC and should be treated. Identification, diagnosis, and treatment of the patient as a whole may improve the patient s overall quality of life and tolerance to cancer treatments. 

Wuchereria bancrofti, a mosquito-transmitted parasite, is the major cause of human lymphatic filariasis in tropic areas. Current estimates suggest that about 120 million people are infected. Infection often leads to microfilaremia without clinical manifestations. The most common clinical presentation of this disease are asymptomatic microfilaremia, filarial fever, and lymphatic obstruction. Ivermectin rapidly reduces microfilaremia concentration in peripheral blood and may inhibit larval development in mosquitoes. Because the drug does not kill adult worms, microfilaremia concentration begins to increase gradually 3-12 months after treatment. 

Clinical presentation. Bile duct complications develop within 2 months of chemoembolization but some may develop at a later stage [27]. Most patients with biliary strictures remain asymptomatic until the lumen of the bile duct is sufficiently narrowed to cause resistance to the flow of bile. Occasionally, patients may have intermittent episodes of RUQ (biliary colic), with or without laboratory features of biliary obstruction. 

---